Search
Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15709ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
RGX-121
go.drugbank.com/drugs/DB17681InvestigationalRGX-121 is designed to use the NAV AAV9 vector to deliver the human iduronate-2-sulfatase gene to the central nervous system.
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]
Spinosad
go.drugbank.com/drugs/DB08823ApprovedVet approvedSpinosad is a pediculicide mixture of spinosyn A and spinosyn D (in an approximately 5:1 ratio, respectively) used in the topical treatment of head lice in children (four years old and older) and in adults
Anakinra
go.drugbank.com/drugs/DB00026ApprovedInvestigationalOn November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. … [L35415] Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as
Andusomeran
go.drugbank.com/drugs/DB18227ApprovedInvestigational[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. [elasomeran], [imelasomeran]), but is designed to be effective against the Omicron XBB.1.5 subvariant.
Topiramate
go.drugbank.com/drugs/DB00273ApprovedInvestigational[A175249] It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. … [A175249] Interestingly, topiramate was discovered by chance when attempts were made to formulate a novel antidiabetic drug.[A188330]
Products: NABIAN-KTechnetium Tc-99m nofetumomab merpentan
go.drugbank.com/drugs/DB09336ApprovedWithdrawnIt was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082] … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992.
Afimoxifene
go.drugbank.com/drugs/DB04468InvestigationalThis technology enables percutaneous delivery of drugs that cannot be delivered orally. It is being developed by Ascent Therapeutics.
Nelarabine
go.drugbank.com/drugs/DB01280ApprovedInvestigational[A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline. … [A15220] Subsequently, nelarabine was also approved by both Health Canada and European Medicines Agency in 2007 under the trademark name ATRIANCE.[L45874,L45879]